TrialLeukemia2016

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.

A Hochhaus et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.